Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.
IgA
IgG4
Oral immunotherapy
Peanut allergy
Saliva
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
07
06
2022
revised:
07
07
2022
accepted:
27
07
2022
pubmed:
10
8
2022
medline:
15
12
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Antigen-specific immunoglobulin responses have yet to be studied at the oral mucosal surface during peanut oral immunotherapy (PnOIT). We aimed to quantify salivary peanut-specific IgG4 (PNsIgG4) and IgA (PNsIgA) and total IgG4 and IgA in participants from the Immune Tolerance Network's IMPACT study, a phase 2 PnOIT trial. Peanut-allergic children, aged 12 months to younger than 48 months at screening, were enrolled and randomized to PnOIT or placebo oral immunotherapy (OIT) for 134 weeks. Per-protocol analysis included 69 PnOIT and 23 placebo participants. Double-blind, placebo-controlled food challenges were conducted at weeks 134 and 160 to assess desensitization and remission, respectively. Saliva samples were collected at baseline and 30, 82, 134, and 160 weeks to quantify PNsIgG4, PNsIgA, and total IgG4 and IgA. Participants who received PnOIT experienced significant increases in PNsIgG4 in saliva, whereas participants on placebo did not (P < .01 at all time points). The PNsIgA/total IgA ratio was also significantly increased in participants treated with PnOIT when compared with those receiving placebo at 30 and 82 weeks (P < .05). During PnOIT, desensitized participants had increased PNsIgA that plateaued, whereas the not desensitized/no remission group did not change over time. Interestingly, when the PnOIT group was evaluated by clinical outcome, PNsIgA was higher at baseline in the not desensitized/no remission group than in the desensitized/remission group (P < .05). PnOIT induces substantial increases in allergen-specific IgG4 and IgA in saliva. These data provide insight into OIT-induced mucosal responses and suggest the utility of these easily obtained samples for biomarker development.
Sections du résumé
BACKGROUND
BACKGROUND
Antigen-specific immunoglobulin responses have yet to be studied at the oral mucosal surface during peanut oral immunotherapy (PnOIT).
OBJECTIVE
OBJECTIVE
We aimed to quantify salivary peanut-specific IgG4 (PNsIgG4) and IgA (PNsIgA) and total IgG4 and IgA in participants from the Immune Tolerance Network's IMPACT study, a phase 2 PnOIT trial.
METHODS
METHODS
Peanut-allergic children, aged 12 months to younger than 48 months at screening, were enrolled and randomized to PnOIT or placebo oral immunotherapy (OIT) for 134 weeks. Per-protocol analysis included 69 PnOIT and 23 placebo participants. Double-blind, placebo-controlled food challenges were conducted at weeks 134 and 160 to assess desensitization and remission, respectively. Saliva samples were collected at baseline and 30, 82, 134, and 160 weeks to quantify PNsIgG4, PNsIgA, and total IgG4 and IgA.
RESULTS
RESULTS
Participants who received PnOIT experienced significant increases in PNsIgG4 in saliva, whereas participants on placebo did not (P < .01 at all time points). The PNsIgA/total IgA ratio was also significantly increased in participants treated with PnOIT when compared with those receiving placebo at 30 and 82 weeks (P < .05). During PnOIT, desensitized participants had increased PNsIgA that plateaued, whereas the not desensitized/no remission group did not change over time. Interestingly, when the PnOIT group was evaluated by clinical outcome, PNsIgA was higher at baseline in the not desensitized/no remission group than in the desensitized/remission group (P < .05).
CONCLUSIONS
CONCLUSIONS
PnOIT induces substantial increases in allergen-specific IgG4 and IgA in saliva. These data provide insight into OIT-induced mucosal responses and suggest the utility of these easily obtained samples for biomarker development.
Identifiants
pubmed: 35944894
pii: S2213-2198(22)00800-5
doi: 10.1016/j.jaip.2022.07.030
pmc: PMC9742136
mid: NIHMS1828567
pii:
doi:
Substances chimiques
Allergens
0
Immunoglobulin G
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3270-3275Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007062
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI109565
Pays : United States
Informations de copyright
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved.
Références
Allergy. 2021 May;76(5):1367-1384
pubmed: 33216994
Cell Mol Life Sci. 2019 Mar;76(6):1041-1055
pubmed: 30498997
J Allergy Clin Immunol. 2014 Dec;134(6):1310-1317.e6
pubmed: 25042981
J Allergy Clin Immunol. 2012 Apr;129(4):1159-62
pubmed: 22236732
Immunol Allergy Clin North Am. 2020 Feb;40(1):87-95
pubmed: 31761123
J Allergy Clin Immunol. 2015 Jul;136(1):125-134.e12
pubmed: 25985925
Sci Immunol. 2020 May 8;5(47):
pubmed: 32385053
Clin Exp Allergy. 2019 Apr;49(4):461-470
pubmed: 30383313
J Vis Exp. 2018 Oct 25;(140):
pubmed: 30417864
J Allergy Clin Immunol. 2015 May;135(5):1249-56
pubmed: 25670011
J Allergy Clin Immunol. 2019 Nov;144(5):1310-1319.e4
pubmed: 31377342
J Allergy Clin Immunol. 2011 Mar;127(3):654-60
pubmed: 21377034
J Allergy Clin Immunol. 2020 Mar;145(3):885-896.e6
pubmed: 31805311
Ann Allergy Asthma Immunol. 2010 Dec;105(6):444-50
pubmed: 21130382
Pediatr Allergy Immunol. 2014 Feb;25(1):64-70
pubmed: 24118158
J Allergy Clin Immunol. 2016 Apr;137(4):973-982
pubmed: 27059725
Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117
pubmed: 29488131
J Allergy Clin Immunol Pract. 2022 May;10(5):1305-1311.e3
pubmed: 35074603
Lancet. 2022 Jan 22;399(10322):359-371
pubmed: 35065784
N Engl J Med. 2015 Feb 26;372(9):803-13
pubmed: 25705822
Infect Immun. 2000 Jul;68(7):3830-9
pubmed: 10858191
J Allergy Clin Immunol. 2014 Feb;133(2):468-75
pubmed: 24361082
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97
pubmed: 19577283